Cefazolin
(Synonyms: 头孢唑啉,Cephazolin) 目录号 : GC60683Cefazolin(Cephazolin) is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
Cas No.:25953-19-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cefazolin(Cephazolin) is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
Cas No. | 25953-19-9 | SDF | |
别名 | 头孢唑啉,Cephazolin | ||
Canonical SMILES | O=C(C(N12)=C(CSC3=NN=C(C)S3)CS[C@]2([H])[C@H](NC(CN4N=NN=C4)=O)C1=O)O | ||
分子式 | C14H14N8O4S3 | 分子量 | 454.51 |
溶解度 | DMSO: 250 mg/mL (550.04 mM) | 储存条件 | 4°C, away from moisture |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2002 mL | 11.0009 mL | 22.0017 mL |
5 mM | 0.44 mL | 2.2002 mL | 4.4003 mL |
10 mM | 0.22 mL | 1.1001 mL | 2.2002 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Cefazolin
Ann Intern Med 1978 Nov;89(5 Pt 1):650-6.PMID:362999DOI:10.7326/0003-4819-89-5-650.
After 5 years of use, Cefazolin can be considered similar to cephalothin as a therapeutic agent and in its potential for adverse reactions. When Cefazolin and cephalothin are compared by appropriately designed clinical trials, neither Cefazolin's slightly greater in-vitro susceptibility to staphylococcal beta-lactamase inactivation, nor its slightly greater microbiologic activity for some enterobacteraciae has been shown to result in any readily apparent therapeutic differences. The important differences between Cefazolin and cephalothin--and this is also probably true with respect to cephapirin and cephradine--are not in therapeutic effectiveness, microbiologic activity, or toxicity but rather in pharmacokinetics and cost-effectiveness.
Cefazolin-induced hypoprothrombinemia
Am J Health Syst Pharm 2008 May 1;65(9):823-6.PMID:18436729DOI:10.2146/ajhp070243.
Purpose: A case of cefazolin-induced hypoprothrombinemia in a patient with renal failure is reported. Summary: A 50-year-old African-American woman was transferred from the orthopedics service to the internal medicine service for management of acute renal failure. Before her transfer, she had spinal surgery and subsequently developed a wound infection complicated by Escherichia coli bacteremia. After trials of multiple antibiotics, she developed acute interstitial nephritis and renal failure. On the day of her transfer to the internal medicine service, i.v. Cefazolin sodium 1 g was administered every 24 hours to eradicate the E. coli detected in blood cultures. Her baseline International Normalized Ratio (INR) was 1.3. On day 7 of Cefazolin therapy, her INR increased to 4.0. Because of her recent history of bleeding and hypotension, vitamin K 10 mg i.v. was administered, followed by 5 mg orally for the next two days. Her INR decreased and normalized at 1.1. The patient had no changes to other drug therapies and had no medical conditions known to independently affect prothrombin time during this episode. The score on the Naranjo et al. adverse-event probability scale revealed a probable relationship between Cefazolin and hypoprothrombinemia in this patient. Conclusion: A patient with a postsurgery wound infection and acute renal failure developed hypoprothrombinemia after receiving Cefazolin for seven days.
A quality assurance initiative on improving Cefazolin perioperative redose compliance
Int J Qual Health Care 2022 Oct 8;34(4):mzac073.PMID:36103371DOI:10.1093/intqhc/mzac073.
Objective: Compliance with perioperative antibiotic prophylaxis is crucial for preventing surgical site infection. Anesthesiologists can play a significant role in reducing surgical site infections by following clinical practice guidelines for antibiotic prophylaxis and redosing during surgery. A quality assurance initiative was implemented at a tertiary hospital with the goal of improving Cefazolin perioperative antibiotic compliance. Design: This was a retrospective observational study. Setting: Main operating room of a tertiary care teaching hospital in New York, USA. Our main operating room includes 22 operating rooms that incorporates surgeries from general surgery, vascular surgery, neurology, gynecology, urology, orthopedics, ear, nose and throat (ENT) etc. Participants: All cases in the main operating room from March 1, 2018 to March 31, 2021 that received first dose of Cefazolin and in which the duration of surgery was more than 4 hrs. Intervention: A multifaceted intervention was initiated to address low compliance with Cefazolin redosing. Multifaceted interventions included the development of a perioperative antibiotic guide for anesthesia providers, automated reminders in anesthesia electronic medical records, grand rounds education, survey and email communications, and regular feedback reports to the anesthesia department. Main outcome measures: Cefazolin perioperative redose compliance rate. Results: Rates of redose compliance were examined in three time periods: preintervention, intervention and postintervention. Cefazolin redosing compliance was 58% in the preintervention period and 90% in the postintervention period. There was a significant positive change in the trend of compliance during the intervention period, indicating that the odds of compliance increased by 13% per month in the intervention period compared to the preintervention period (odds ratio = 1.13, P < 0.001). Redose compliance improvements were sustained a year after the postintervention period (an average of 91%). Surgical site infection rates for colon, coronary artery bypass graft and hip surgeries did not show any significant trend during these time periods. Conclusion: Multifaceted interventions led to significant and sustained improvements in Cefazolin redosing compliance in the main operating room of a tertiary hospital.
Cefazolin pharmacokinetics in cats under surgical conditions
J Feline Med Surg 2017 Oct;19(10):992-997.PMID:27609113DOI:10.1177/1098612X16666594.
Objectives The aim of this study was to determine the plasma pharmacokinetic profile, tissue concentrations and urine elimination of Cefazolin in cats under surgical conditions after a single intravenous dose of 20 mg/kg. Methods Intravenous Cefazolin (20 mg/kg) was administered to nine young mixed-breed cats 30 mins before they underwent surgical procedures (ovariectomy or orchiectomy). After antibiotic administration, samples from blood, some tissues and urine were taken. Cefazolin concentrations were determined in all biological matrices and pharmacokinetic parameters were estimated. Results Initial plasma concentrations were high (Cp(0), 134.80 ± 40.54 µg/ml), with fast and moderately wide distribution (distribution half-life [t½(d)] 0.16 ± 0.15 h; volume of distribution at steady state [V(d[ss])] 0.29 ± 0.10 l/kg) and rapid elimination (body clearance [ClB], 0.21 ± 0.06 l/h/kg; elimination half-life [t½], 1.18 ± 0.27 h; mean residence time 1.42 ± 0.36 h). Thirty to 60 mins after intravenous administration, Cefazolin tissue concentrations ranged from 9.24 µg/ml (subcutaneous tissue) to 26.44 µg/ml (ovary). The tissue/plasma concentration ratio ranged from 0.18 (muscle) to 0.58 (ovary). Cefazolin urine concentrations were high with 84.2% of the administered dose being eliminated in the first 6 h postadministration. Conclusions and relevance Cefazolin plasma concentrations remained above a minimum inhibitory concentration of ⩽2 µg/ml up to 4 h in all the studied cats. This suggests that a single intravenous dose of 20 mg/kg Cefazolin would be adequate for perioperative prophylactic use in cats.
Stability of Cefazolin in Polyisoprene Elastomeric Infusion Devices
Clin Ther 2018 Apr;40(4):664-667.PMID:29496321DOI:10.1016/j.clinthera.2018.02.009.
Purpose: The aim was to investigate the stability of Cefazolin in elastomeric infusion devices. Methods: Elastomeric devices (Infusor LV) that contain Cefazolin (3 g/240 mL and 6 g/240 mL) were prepared and stored at 4°C for 72 hours and then at 35°C for 12 hours, followed by 25°C for 12 hours. An aliquot was withdrawn at predefined time points and analyzed for the concentration of Cefazolin. Samples were also assessed for changes in pH, solution color, and particle content. Findings: Cefazolin retained acceptable chemical and physical stability over the studied storage period and conditions. Implications: These findings will allow the administration of Cefazolin by the Infusor LV elastomeric device in the outpatient and remote settings.